Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

被引：0

作者：

Levy, Michael ^{[1
,2
]}

Pittock, Sean ^{[3
]}

Barnett, Michael ^{[4
]}

Bennett, Jeffrey ^{[5
,6
]}

Berthele, Achim ^{[7
]}

De Seze, Jerome ^{[8
,9
]}

Nakashima, Ichiro ^{[10
,11
]}

Guevara, Celia Oreja ^{[12
,13
]}

Palace, Jacqueline ^{[14
]}

Paul, Friedemann ^{[15
,16
,17
]}

Pozzilli, Carlo ^{[18
]}

Allen, Kerstin ^{[19
]}

Mashhoon, Yasmin ^{[19
]}

Yountz, Marcus ^{[19
]}

Kim, Ho Jin ^{[20
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[4] Royal Prince Alfred Hosp, Dept Neurol, Sydney, NSW, Australia

[5] Univ Colorado, Programs Neurosci & Immunol, Dept Neurol, Aurora, CO USA

[6] Univ Colorado, Programs Neurosci & Immunol, Dept Ophthalmol, Aurora, CO USA

[7] Tech Univ Munich, Sch Med, Dept Neurol, Munich, Germany

[8] CHU Strasbourg, Dept Neurol, Strasbourg, France

[9] CHU Strasbourg, Clin Invest Ctr, Strasbourg, France

[10] Tohoku Univ Grad Sch Med, Dept Neurol, Sendai, Miyagi, Japan

[11] Tohoku Med & Pharmaceut Univ, Div Neurol, Sendai, Miyagi, Japan

[12] IdISCC, Hosp Clinico Univ San Carlos, Dept Neurol, Madrid, Spain

[13] Univ Complutense Madrid, Dept Med, Madrid, Spain

[14] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England

[15] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, Berlin, Germany

[16] Max Delbruck Ctr Mol Med, Neurocure Clin Res Ctr, Berlin, Germany

[17] Charite Univ Med Berlin, Berlin, Germany

[18] Univ Sapienza, Dept Human Neurosci, Rome, Italy

[19] Alexion, AstraZeneca Rare Dis, Boston, MA USA

[20] Natl Canc Ctr, Dept Neurol, Goyang, South Korea

来源：

NEUROLOGY | 2023年 / 100卷 / 17期

关键词：

D O I：

10.1212/WNL.0000000000203035

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S5.003

引用

页数：8

共 50 条

[1] Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Pittock, S. J.
Barnett, M.
Bennett, J. L.
Berthele, A.
de Seze, J.
Levy, M.
Nakashima, I.
Oreja-Guevara, C.
Palace, J.
Paul, F.
Pozzilli, C.
Allen, K.
Mashhoon, Y.
Yountz, M.
Kim, H. J.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 136 - 137
[2] Efficacy Subgroup Analyses From the Phase 3 CHAMPION-NMOSD Trial in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder
Barnett, Michael
Pittock, Sean J.
Bennett, Jeffrey L.
Berthele, Achim
de Seze, Jerome
Levy, Michael
Nakashima, Ichiro
Oreja-Guevara, Celia
Palace, Jacqueline
Paul, Friedemann
Pozzilli, Carlo
Allen, Kerstin
Mashhoon, Yasmin
Yountz, Marcus
Kim, Ho Jin
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP26 - NP28
[3] Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial
Pittock, S. J.
Barnett, M.
Bennett, J. L.
Berthele, A.
de Seze, J.
Levy, M.
Nakashima, I.
Oreja-Guevara, C.
Palace, J.
Paul, F.
Pozzilli, C.
Allen, K.
Mashhoon, Y.
Yountz, M.
Kim, H. J.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 39 - 40
[4] Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial
Pittock, Sean
Barnett, Michael
Bennett, Jeffrey
Berthele, Achim
De Seze, Jerome
Levy, Michael
Nakashima, Ichiro
Oreja-Guevara, Celia
Palace, Jacqueline
Paul, Friedemann
Pozzilli, Carlo
Allen, Kerstin
Mashhoon, Yasmin
Yountz, Marcus
Kim, Ho Jin
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[5] Efficacy and Safety of Ravulizumab in Adults With Anti-aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Outcomes From the Phase 3 CHAMPION-NMOSD Trial
Kim, Ho Jin
Barnett, Michael
Bennett, Jeffrey
Berthele, Achim
de Seze, Jerome
Levy, Michael
Nakashima, Ichiro
Oreja-Guevara, Celia
Palace, Jacqueline
Paul, Friedemann
Pozzilli, Carlo
Allen, Kerstin
Mashhoon, Yasmin
Yountz, Marcus
Pittock, Sean
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP30 - NP31
[6] Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial
Pittock, Sean
Barnett, Michael
Bennett, Jeffrey
Berthele, Achim
De Seze, Jerome
Levy, Michael
Nakashima, Ichiro
Guevara, Celia Oreja
Palace, Jacqueline
Paul, Friedemann
Pozzilli, Carlo
Allen, Kerstin
Mashhoon, Yasmin
Yountz, Marcus
Kim, Ho Jin
NEUROLOGY, 2023, 100 (17)
[7] Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION-NMOSD trial
Ortiz, Stephan
Pittock, Sean
Berthele, Achim
Levy, Michael
Nakashima, Ichiro
Guevara, Celia Oreja
Kim, Ho Jin
NEUROLOGY, 2023, 100 (17)
[8] Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Pittock, S.
Berthele, A.
Fujihara, K.
Kim, H. J.
Levy, M.
Palace, J.
Terzi, M.
Totolyan, N.
Viswanathan, S.
Wang, K. -C.
Pace, A.
Fujita, K. P.
Yountz, M.
Armstrong, R.
Wingerchuk, D. M.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 289 - 290
[9] Serum anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder presenting as acute eosinophilic encephalomyelitis
Muroishi, Toyoteru
Sakai, Kenji
Yanase, Daisuke
Ikeda, Yoshihisa
Machiya, Tomohiko
Kato-Motozaki, Yuko
Samuraki, Miharu
Yamada, Masahito
JOURNAL OF CLINICAL NEUROSCIENCE, 2018, 48 : 93 - 94
[10] Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Akaishi, Tetsuya
Himori, Noriko
Takeshita, Takayuki
Fujihara, Kazuo
Misu, Tatsuro
Takahashi, Toshiyuki
Fujimori, Juichi
Ishii, Tadashi
Aoki, Masashi
Nakazawa, Toru
Nakashima, Ichiro
BRAIN AND BEHAVIOR, 2021, 11 (05):

← 1 2 3 4 5 →